
March 28, 2025
Trump Yet To Clarify Tariffs On Healthcare Products Donald Trump has yet to decide how potential tariffs on pharmaceutical products will be structured. In February, Trump said that tariffs on pharmaceuticals and other essential products would be about 25% and that U.S. companies may get a phase-in period for imported goods, giving them time to shift production onshore. In a new survey of 200 healthcare industry experts, 82% said they expect tariff-related import expenses to increase hospital and health system costs by 15%. So, most of the tariff costs will be passed through. Additional article: https://www.beckershospitalreview.com/supply-chain/hospital-finance-supply-leaders-predict-15-increase-in-tariff-related-costs/ (Some articles may require a subscription.) #drugpricing #branddrugmakers #tariffs https://insidehealthpolicy.com/inside-drug-pricing-daily-news/trump-undecided-structure-potential-pharma-tariffs-wh-says HCSC Joins Big Leagues An interesting article on Health Care Service Corporation’s recent acquisition of Cigna’s Medicare businesses. While Medicare Advantage (MA) has significant headwinds, HCSC leadership believes in MA’s long-term viability. It does not plan to become as much of a behemoth as the big
